Serina Therapeutics Sells UniverXome Subsidiary

Dow Jones

Jan 16, 2025

By Stephen Nakrosis

Serina Therapeutics on Wednesday said it has sold its UniverXome subsidiary in a deal which was finalized on Dec. 23.

The biotechnology company said on Wednesday that the transaction eliminated $11.2 million in associated subsidiary-level debt, allowing the company to enter 2025 with a debt-free balance sheet.

Chief Executive Officer Steve Ledger said the deal allows Serina to continue its focus on advancing SER-252, its lead candidate for advanced Parkinson's disease, into clinical development. The deal also allows the company to further explore the potential of its POZ platform, a technology designed to provide greater control in drug loading and the rate of release of drugs delivered via subcutaneous injection, Ledger said.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

January 15, 2025 16:33 ET (21:33 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2503928670"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503928670\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2503928670?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-16 05:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503928670","market":"us","top_or_hot":-1,"title":"Serina Therapeutics Sells UniverXome Subsidiary","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Serina <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> on Wednesday said it has sold its UniverXome subsidiary in a deal which was finalized on Dec. 23. \n</p>\n<p>\n  The biotechnology company said on Wednesday that the transaction eliminated $11.2 million in associated subsidiary-level debt, allowing the company to enter 2025 with a debt-free balance sheet. \n</p>\n<p>\n  Chief Executive Officer Steve Ledger said the deal allows Serina to continue its focus on advancing SER-252, its lead candidate for advanced Parkinson's disease, into clinical development. The deal also allows the company to further explore the potential of its POZ platform, a technology designed to provide greater control in drug loading and the rate of release of drugs delivered via subcutaneous injection, Ledger said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 15, 2025 16:33 ET (21:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Serina Therapeutics Sells UniverXome Subsidiary</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSerina Therapeutics Sells UniverXome Subsidiary\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-16 05:33</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Serina <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> on Wednesday said it has sold its UniverXome subsidiary in a deal which was finalized on Dec. 23. \n</p>\n<p>\n  The biotechnology company said on Wednesday that the transaction eliminated $11.2 million in associated subsidiary-level debt, allowing the company to enter 2025 with a debt-free balance sheet. \n</p>\n<p>\n  Chief Executive Officer Steve Ledger said the deal allows Serina to continue its focus on advancing SER-252, its lead candidate for advanced Parkinson's disease, into clinical development. The deal also allows the company to further explore the potential of its POZ platform, a technology designed to provide greater control in drug loading and the rate of release of drugs delivered via subcutaneous injection, Ledger said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 15, 2025 16:33 ET (21:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SER","symbol_name":"Serina Therapeutics, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2503928670","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503928670","pubTimestamp":1736976780,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Serina Therapeutics on Wednesday said it has sold its UniverXome subsidiary in a deal which was finalized on Dec. 23.The biotechnology company said on Wednesday that the transaction eliminated $11.2 million in associated subsidiary-level debt, allowing the company to enter 2025 with a debt-free balance sheet.Chief Executive Officer Steve Ledger said the deal allows Serina to continue its focus on advancing SER-252, its lead candidate for advanced Parkinson's disease, into clinical development. The deal also allows the company to further explore the potential of its POZ platform, a technology designed to provide greater control in drug loading and the rate of release of drugs delivered via subcutaneous injection, Ledger said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SER":"Serina Therapeutics, Inc.","BK4139":"生物科技","LENZ":"Therapeutics"},"translate_title":"Serina Therapeutics出售UniverXome子公司","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SER":0.9,"LENZ":1},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Serina Therapeutics on Wednesday said it has sold its UniverXome subsidiary in a deal which was finalized on Dec. 23. \n\n\n  The biotechnology company said on Wednesday that the transaction eliminated $11.2 million in associated subsidiary-level debt, allowing the company to enter 2025 with a debt-free balance sheet. \n\n\n  Chief Executive Officer Steve Ledger said the deal allows Serina to continue its focus on advancing SER-252, its lead candidate for advanced Parkinson's disease, into clinical development. The deal also allows the company to further explore the potential of its POZ platform, a technology designed to provide greater control in drug loading and the rate of release of drugs delivered via subcutaneous injection, Ledger said. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 15, 2025 16:33 ET (21:33 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}